Surmodics is the global leader in surface modification technologies for vascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) tests and microarrays.
Following two acquisitions of Creagh Medical and NorMedix – recognized innovators in balloon catheters and delivery systems – we have combined capabilities in proprietary surface technologies, as well as device design, development and manufacturing that enable us to significantly increase the value we offer our medical device customers. We are focused on developing highly differentiated, total vascular device solutions to the most demanding clinical challenges. The company’s R&D pipeline is rich with novel innovations within the field of vascular medicine. Even as we expand our capabilities, our mission remains to improve the detection and treatment of disease.
Surmodics is headquartered in Eden Prairie, Minnesota and we have a state-of-the-art manufacturing and research and development (R&D) facility in Ballinasloe, Ireland. LEARN MORE.
Surmodics history of leadership
Surmodics’ leadership in surface technologies for medical devices goes back to the development of the drug-delivery technology for the industry’s first-ever drug-eluting stent. The Surmodics team brings a depth of expertise and contributions to industry innovation, including embolic protection, transcatheter mitral valve repair, left atrial appendage closure and catheter microcoils. One in three Surmodics employees are scientists or engineers, and they contribute to an average of 41 patents issued to the company each year.